A possible cause and remedy for the clinical failure of 5-fluorouracil plus eniluracil

Clinical Colorectal Cancer

Volumn 9, Issue 1, 2010, Pages 52-54

  Spector, Thomas ^a,b   Cao, Shousong ^c  

^a Spector Consulting Services   (United States)

^b Adherex Technologies Inc   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

5 FU; Antitumor efficacy; Dihydropyrimidine dehydrogenase; DPD

Indexed keywords

5 ETHYNYLURACIL; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; NONHUMAN; RAT; TUMOR REGRESSION; TUMOR VOLUME;

EID: 77149146798     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2010.n.007     Document Type: Article

References (17)

1. Spector T, Porter DJ, Nelson DJ, et al. 5-Ethynyluracil (776C85), A modulator of the therapeutic activity of 5-fluorouracil. Drugs Future 1994; 19:565-571
2. Paff MT, Baccanari DP, Davis ST, et al. Preclinical development of eniluracil: enhancing the therapeutic index and dosing convenience of 5-fluorouracil. Invest New Drugs 2000; 18:365-371
3. Adjei AA, Reid JM, Diasio RB, et al. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. J Clin Oncol 2002; 20:1683-1691
4. Ochoa L, Hurwitz HI, Wilding G, et al. Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. Ann Oncol 2000; 11:1313-1322
5. Baker SD. Pharmacology of fluorinated pyrimidines: eniluracil. Invest New Drugs 2000; 18:373-381
6. Baker SD, Khor SP, Adjei AA, et al. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 1996; 14:3085-3096
7. Guo XD, Harold N, Saif MW, et al. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule. Cancer Chemother Pharmacol 2003; 52:79-85.
8. Schilsky RL, Hohneker J, Ratain MJ, et al. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol 1998; 16:1450-1457
9. Cao S, Rustum YM, Spector T. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 1994; 54:1507-1510
10. Baker SD, Diasio RB, O'Reilly S, et al. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. J Clin Oncol 2000; 18:915-926
11. Levin J, Hohneker J. Clinical development of eniluracil/fluorouracil: an oral treatment for patients with solid tumors. Invest New Drugs 2000; 18:383-390
12. Schilsky RL, Kindler HL. Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. Expert Opin Investig Drugs 2000; 9:1635-1649
13. Schilsky RL, Levin J, West WH, et al. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J Clin Oncol 2002; 20:1519-1526
14. Fourie JG, Guarcello V, Diasio RB. Dose dependent inhibition of uridine phosphorylase (UP) by eniluracil (EU): was the clinical inferiority of the EU/5-fluorouracil (5-FU) phase III trials due to an unrecognized inhibition of 5-FU anabolism? J Clin Oncol 2006; 24:2058.
15. Spector T, Harrington JA, Porter DJ. 5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem Pharmacol 1993; 46:2243-2248
16. Heslin MJ, Yan J, Weiss H, et al. Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer. Cancer Chemother Pharmacol 2003; 52:399-404.
17. Davis ST, Joyner SS, Baccanari DP, et al. 5-Ethynyluracil (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs. Biochem Pharmacol 1994; 48:233-236